An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer

Maryum Nisar; Rehan Zafar Paracha; Sidra Adil; Sumair Naseem Qureshi; Hussnain Ahmed Janjua

doi:10.3389/fonc.2022.875188

An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer

Front Oncol. 2022 May 24:12:875188. doi: 10.3389/fonc.2022.875188. eCollection 2022.

Authors

Maryum Nisar¹, Rehan Zafar Paracha¹, Sidra Adil¹, Sumair Naseem Qureshi², Hussnain Ahmed Janjua³

Affiliations

¹ School of Interdisciplinary Engineering & Sciences (SINES), National University of Sciences and Technology (NUST), Islamabad, Pakistan.
² Shifa College of Medicine, Islamabad, Pakistan.
³ Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Sector H-12, Islamabad, Pakistan.

Abstract

Chemotherapy resistance and peculiar tumor microenvironment, which diminish or mitigate the effects of therapies, make pancreatic cancer one of the deadliest malignancies to manage and treat. Advanced immunotherapies are under consideration intending to ameliorate the overall patient survival rate in pancreatic cancer. Oncolytic viruses therapy is a new type of immunotherapy in which a virus after infecting and lysis the cancer cell induces/activates patients' immune response by releasing tumor antigen in the blood. The current review covers the pathways and molecular ablation that take place in pancreatic cancer cells. It also unfolds the extensive preclinical and clinical trial studies of oncolytic viruses performed and/or undergoing to design an efficacious therapy against pancreatic cancer.

Keywords: Adenovirus; clinical trials; immunotherapy; oncolytic virus therapy; pancreatic cancer; preclinical studies; recombinant virus; therapy-resistance.

Publication types

Review